Aehr Test Systems
AEHR
$98.91
+27.86%
Aehr Test Systems designs, manufactures, and sells advanced test and burn-in systems for logic, optical, and memory integrated circuits, serving the semiconductor manufacturing industry. The company is a niche leader in semiconductor test equipment, particularly known for its FOX-PT and ABTS product families that address the growing quality and reliability needs of automotive and mobility IC markets. The current investor narrative centers on Aehr's strategic pivot from electric vehicle (EV) testing to AI processor testing, which drove record bookings and a 20% stock surge in July 2026, with revenue expected to triple next year as AI infrastructure spending accelerates.…
AEHR
Aehr Test Systems
$98.91
Related headlines
Investment Opinion: Should I buy AEHR Today?
Rating: Buy. Thesis: Aehr Test Systems is a high-growth semiconductor equipment play riding the AI infrastructure wave, with record bookings and accelerating revenue that justify its premium valuation, though investors must accept extreme volatility. The consensus analyst rating is Strong Buy with an average target of $108.33, implying 33.7% upside.
Supporting Evidence: (1) Revenue grew 40.2% YoY in Q4 FY2026 to $19.8 million, with analyst estimates projecting a tripling to $196.1 million next year. (2) Gross margin improved to 40.6% from 30.3% a year ago, showing operating leverage. (3) The company turned profitable with net income of $1.4 million in Q4, compared to a -$2.9 million loss last year. (4) Free cash flow turned positive at $1.1 million in Q4, signaling improving cash generation. (5) The forward P/S of 14.4x, while a premium to the industry average of 5-8x, is near the lower end of Aehr's historical range (11x-143x), suggesting the stock is not overvalued relative to its own history if growth materializes.
Risks & Conditions: The biggest risks are (1) failure to sustain the AI-driven revenue growth, (2) multiple compression if growth decelerates, and (3) customer concentration. This Buy rating would be downgraded to Hold if revenue growth falls below 20% YoY or if the stock loses support below $66.94 (recent low). It would be upgraded if the company raises guidance or secures additional large orders. Overall, Aehr is fairly valued relative to its growth trajectory but overvalued on trailing metrics — the investment hinges on execution.
Sign up to view all
AEHR 12-Month Price Forecast
Aehr Test Systems is positioned at the intersection of two powerful trends: AI infrastructure build-out and semiconductor testing demand. The company's pivot from EVs to AI processors has already generated tangible results — record bookings, accelerating revenue, and a return to profitability. The valuation, while high on trailing metrics, is justified by the expected growth trajectory, with a forward P/S of 14.4x that is reasonable for a company expected to triple revenue. However, the extreme volatility (beta 3.183) and recent 28% correction highlight the risk. The base case of achieving analyst targets is the most probable, but the bull case could materialize if AI spending accelerates further. I would upgrade to high confidence if the company reports another quarter of accelerating revenue and positive EPS. The stance is bullish given the strong execution and favorable demand backdrop, but with medium confidence due to valuation and volatility risks.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Aehr Test Systems's 12-month outlook, with a consensus price target around $115.00 and implied upside of +16.3% versus the current price.
Average Target
$115.00
0 analysts
Implied Upside
+16.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$110 - $125
Analyst target range
Aehr is covered by 3 analysts, with a consensus recommendation of Strong Buy (mean score 1.5 on a 1-5 scale). The average target price is $108.33, implying approximately 33.7% upside from the current price of $81.05. The distribution shows no Hold or Sell ratings, indicating unanimous bullish sentiment among the covering analysts.
The target price range spans from $90.00 (low) to $125.00 (high), representing a spread of $35.00 or 38.9% of the current price, indicating moderate uncertainty. The high target of $125.00 assumes the company successfully executes its AI pivot and achieves the upper end of revenue estimates ($225.6 million), while the low target of $90.00 may price in more conservative growth or margin pressure. Recent institutional ratings show upgrades: William Blair upgraded from Market Perform to Outperform in March 2026, and Craig-Hallum upgraded from Hold to Buy (implied by action change) in January 2026, reflecting growing confidence in the AI-driven growth story.
Drowning in data?
Find the real signal!
Bulls vs Bears: AEHR Investment Factors
Aehr Test Systems presents a high-risk, high-reward opportunity. The bull case is compelling: a successful pivot to AI processor testing has driven record bookings, accelerating revenue growth, a return to profitability, and a fortress balance sheet. Analysts are unanimously bullish, with an average target implying 33.7% upside. However, the bear case is equally strong: the stock trades at a massive valuation premium (trailing P/S 56.6x vs. industry 5-8x), has negative trailing earnings, extreme volatility (beta 3.183), and has already corrected 28% in the past month. The single most important tension is whether Aehr can sustain its AI-driven revenue growth trajectory — if it does, the forward P/S of 14.4x may prove cheap; if it stumbles, the stock could re-rate sharply lower. Currently, the bull case has stronger evidence given the tangible bookings and revenue inflection, but the valuation leaves no room for error.
Bullish
- AI Pivot Driving Record Bookings: Aehr's strategic shift from EV to AI processor testing generated record bookings of $37.2 million in Q4 FY2026, with revenue expected to triple next year to $196.1 million (analyst consensus). This pivot positions Aehr to capitalize on the booming AI infrastructure build-out, as evidenced by a 20% stock surge in July 2026.
- Revenue Growth Accelerating Sharply: Q4 FY2026 revenue of $19.8 million grew 40.2% year-over-year, up from $14.1 million in the prior-year quarter. This marks a significant inflection from earlier FY2026 quarters where revenue ranged from $9.9 million to $10.9 million, indicating strong momentum driven by AI-related orders.
- Profitability Inflection Achieved: Aehr turned profitable in Q4 FY2026, reporting net income of $1.4 million and EPS of $0.05, compared to a net loss of $2.9 million in the same quarter last year. Gross margin improved to 40.6% from 30.3% a year ago, reflecting better product mix and operating leverage.
- Fortress Balance Sheet with Zero Debt: Aehr holds $116.5 million in cash with zero debt, resulting in a debt-to-equity ratio of just 0.045 and a current ratio of 10.33. This provides ample liquidity to fund growth without external financing, reducing financial risk.
Bearish
- Extreme Valuation Premium: Aehr's trailing P/S ratio of 56.6x is over 600% above the semiconductor equipment industry average of 5-8x. Even the forward P/S of 14.4x, based on aggressive revenue estimates, remains a significant premium, leaving little room for execution missteps.
- Negative Trailing Earnings: Despite a profitable Q4, Aehr's trailing twelve-month net income is -$5.4 million, and the operating margin is -28.3%. The company is still in early stages of profitability, and any slowdown in revenue growth could delay sustained positive earnings.
- High Beta and Recent Correction: With a beta of 3.183, Aehr is over three times more volatile than the market. The stock has corrected 28.0% in the past month and 36% from its 52-week high of $126.62, indicating significant downside risk in a market downturn.
- Revenue Concentration Risk: Aehr's revenue is heavily dependent on a few large customers in the AI chip testing market. The Q4 FY2026 surge was driven by a single $37.2 million booking, and any loss of a key customer or order delay could severely impact revenue.
AEHR Technical Analysis
Aehr Test Systems is in a powerful long-term uptrend, with the stock surging 423.6% over the past year, dramatically outperforming the S&P 500's 18.4% gain. The current price of $81.05 sits at 59.5% of its 52-week range ($14.99 low to $126.62 high), indicating the stock has pulled back from its highs but remains well above its lows, suggesting a consolidation phase after a massive rally rather than a trend reversal. The stock's beta of 3.183 implies it is over three times more volatile than the market, amplifying both upside and downside moves.
Short-term momentum has turned sharply negative, with the stock losing 28.0% over the past month and 3.4% over the past three months, diverging from the strong 1-year uptrend. This divergence could signal a temporary pullback or profit-taking after the stock's parabolic rise from $14.99 to $126.62, rather than a fundamental deterioration. The 1-month relative strength of -28.3% versus the S&P 500's +0.3% confirms the stock is undergoing a significant short-term correction.
Key technical support lies near the 52-week low of $14.99, though a more immediate support level may form around the $66.94 area (July 7 low). Resistance is at the 52-week high of $126.62, and a breakout above that level would signal a resumption of the uptrend. Conversely, a breakdown below $66.94 could indicate further downside risk. The stock's extreme beta of 3.183 means it is highly sensitive to market moves, requiring careful position sizing for risk management.
Beta
3.18
3.18x market volatility
Max Drawdown
-42.6%
Largest decline past year
52-Week Range
$16-$127
Price range past year
Annual Return
+501.3%
Cumulative gain past year
| Period | AEHR Return | S&P 500 |
|---|---|---|
| 1m | -14.2% | +0.2% |
| 3m | +1.6% | +5.2% |
| 6m | +220.0% | +8.6% |
| 1y | +501.3% | +19.0% |
| ytd | +346.3% | +9.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AEHR Fundamental Analysis
Aehr's revenue trajectory is accelerating, with Q4 FY2026 (ending May 2026) revenue of $19.8 million growing 40.2% year-over-year, up from $14.1 million in the prior-year quarter. This marks a significant improvement from the earlier quarters of FY2026, where revenue ranged from $9.9 million to $10.9 million, indicating a strong inflection point driven by AI-related orders. The revenue segments show Systems contributing $6.8 million, Contactors $2.6 million, and Services $1.6 million, with Systems being the primary growth driver as AI chip testing demand surges.
The company turned profitable in Q4 FY2026, reporting net income of $1.4 million and EPS of $0.05, compared to a net loss of $2.9 million in the same quarter last year. Gross margin improved to 40.6% from 30.3% a year ago, reflecting better product mix and operating leverage. However, for the trailing twelve months, net income remains negative at -$5.4 million, and the operating margin is -28.3%, indicating the company is still in the early stages of profitability but on a positive trajectory.
Aehr maintains a fortress balance sheet with $116.5 million in cash and zero debt, resulting in a debt-to-equity ratio of just 0.045. The current ratio of 10.33 indicates ample liquidity to fund operations and growth. Free cash flow turned positive at $1.1 million in Q4 FY2026, compared to negative free cash flow in prior quarters, signaling improving cash generation. The company's ROE of -3.2% is negative due to trailing losses, but the strong cash position and lack of debt provide financial flexibility to invest in growth without external financing.
Quarterly Revenue
$19751000.0B
2026-05
Revenue YoY Growth
+40.2%
YoY Comparison
Gross Margin
40.6%
Latest Quarter
Free Cash Flow
$-5376000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AEHR Overvalued?
Since Aehr's trailing net income is negative (TTM net income of -$5.4 million), the trailing P/E ratio of -401.4x is not meaningful. Therefore, we use the price-to-sales (P/S) ratio as the primary valuation metric. The trailing P/S ratio stands at 56.6x, while the forward P/S (based on estimated revenue of $196.1 million) is approximately 14.4x, implying the market expects a massive revenue ramp that would compress the multiple significantly if realized.
Compared to the semiconductor equipment industry average P/S of roughly 5-8x, Aehr's trailing P/S of 56.6x represents a massive premium of over 600%. However, this premium may be justified by the company's expected revenue growth of nearly 300% next year (from $55.8 million TTM to $196.1 million estimated). The forward P/S of 14.4x is still a premium to the industry but more reasonable given the growth trajectory.
Historically, Aehr's P/S ratio has ranged from about 11x to 143x over the past two years. The current trailing P/S of 56.6x is near the middle of this range, suggesting the stock is not at extreme valuation levels relative to its own history. The forward P/S of 14.4x is near the lower end of the historical range, implying that if the company delivers on revenue estimates, the stock could be undervalued relative to its own past multiples.
PE
-401.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~168x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-232.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Aehr's primary financial risk is its negative trailing earnings and thin profitability. Despite a profitable Q4, the TTM net income is -$5.4 million and the operating margin is -28.3%, meaning the company is still burning cash on an annual basis. The high gross margin improvement to 40.6% is encouraging, but any revenue shortfall could quickly reverse the profitability gains. Additionally, with only $116.5 million in cash and no debt, the company has a cushion, but the cash burn rate (TTM FCF of -$5.4 million) needs to turn sustainably positive to justify the valuation.
Market & Competitive Risks: The stock's beta of 3.183 makes it highly sensitive to market downturns, and the recent 28% monthly correction demonstrates this risk. The trailing P/S of 56.6x is a massive premium to the semiconductor equipment industry average of 5-8x, leaving the stock vulnerable to multiple compression if growth decelerates. Competitive risks include larger players like Teradyne or Advantest potentially entering the AI chip testing niche, which could erode Aehr's market share. The narrow analyst coverage (3 analysts) also means less institutional support and potentially higher volatility.
Worst-Case Scenario: If AI infrastructure spending slows or Aehr loses a key customer, revenue growth could disappoint, leading to multiple compression. In a severe downturn, the stock could retest its 52-week low of $14.99, representing a potential loss of -81.5% from the current price of $81.05. The historical max drawdown of -42.58% suggests that even in moderate corrections, investors could face significant losses. The bear case target of $90.00 (analyst low) implies a more modest 11% upside, but if fundamentals deteriorate, the stock could fall well below that level.
FAQ
The key risks are: (1) Financial risk: negative trailing earnings (TTM net income -$5.4M) and thin profitability, though Q4 showed improvement. (2) Valuation risk: trailing P/S of 56.6x leaves no room for error; any growth disappointment could trigger severe multiple compression. (3) Market risk: beta of 3.183 means the stock is highly sensitive to market downturns, as evidenced by the 28% monthly correction. (4) Customer concentration risk: the recent $37.2 million booking highlights dependence on a few large AI chip customers. (5) Competitive risk: larger players like Teradyne could enter the niche. The most severe risk is a slowdown in AI spending, which could lead to a -81.5% decline to the 52-week low.
The 12-month forecast is based on three scenarios. The base case (45% probability) assumes Aehr achieves analyst consensus revenue of $196.1 million, with the stock trading near the average target of $108.33 (33.7% upside). The bull case (30% probability) sees revenue exceeding $225 million, driving the stock to the high target of $125.00 (54.2% upside). The bear case (25% probability) involves a growth slowdown, with the stock falling to the low target of $90.00 (11.1% upside) or lower to $66.94 (17.4% downside). The most likely scenario is the base case, given the strong bookings momentum but high valuation. Key assumptions include sustained AI infrastructure spending and successful execution on the AI pivot.
Aehr's valuation is a tale of two metrics. On a trailing basis, the P/S ratio of 56.6x is extremely overvalued compared to the semiconductor equipment industry average of 5-8x. However, on a forward basis, using analyst consensus revenue of $196.1 million, the forward P/S is approximately 14.4x, which is near the lower end of Aehr's historical range of 11x to 143x. This implies the market is pricing in the expected revenue tripling, and if the company delivers, the stock could be undervalued relative to its own history. The PEG ratio is negative due to negative earnings, making it unhelpful. Overall, the stock is overvalued on trailing metrics but may be fairly valued to undervalued if the growth materializes.
Aehr Test Systems is a high-risk, high-reward buy for aggressive investors who believe in the long-term AI infrastructure theme. The stock has strong momentum with record bookings, accelerating revenue (40.2% YoY growth in Q4), and a return to profitability. Analysts are unanimously bullish with an average target of $108.33, implying 33.7% upside. However, the stock trades at a trailing P/S of 56.6x, far above the industry average, and has extreme volatility (beta 3.183). The biggest downside risk is a slowdown in AI spending, which could cause the stock to retest its 52-week low of $14.99 (81.5% downside). For investors with a high risk tolerance and a 12-month horizon, it could be a good buy, but conservative investors should avoid it.
Aehr is best suited for a long-term investment horizon of at least 12-24 months, given its early-stage growth profile and extreme volatility. The company is in the early innings of an AI-driven growth cycle, and the revenue tripling expected next year could take time to materialize. Short-term trading is risky due to the stock's high beta (3.183) and recent 28% correction, which could continue. The stock has no dividend, so it offers no income. For long-term investors, the potential reward is significant if the AI infrastructure theme plays out, but they must be prepared for drawdowns of 40% or more (historical max drawdown -42.58%). A minimum holding period of 18 months is recommended to allow the growth story to unfold.
